1.	Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110011, 11-C-0011, NCT01236573
2.	T-Cells Transduced With Either CXCR2 or Nerve Growth Factor Receptor (NGFR) Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 14 and over Sponsor: NCI, Other Protocol IDs: 2009-0471, NCT01740557
3.	Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CD-2007-01, NCT00610389
4.	Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: J0997, NA_00029491, NCT01045460
5.	Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110123, 11-C-0123, NCT01319565
6.	A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 110260, 11-C-0260, NCT01468818
7.	A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120116, 12-C-0116, NCT01585428
8.	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16992, NCT01659151
9.	Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2643.00, NCI-2013-00486, P30CA015704, NCT01807182
10.	Adoptive T Cell Therapy for Metastatic Ocular Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI Protocol IDs: 130093, 13-C-0093, NCT01814046
11.	A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: SenU-200902002-2, NCT01462903
12.	Vemurafenib and White Blood Cell Therapy for Advanced Melanoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120114, 12-C-0114, NCT01585415
13.	Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-17057, CA184-213, NCT01701674